Adventris Pharmaceuticals
New accelerator entry · 2023-01-31 · the record
In their words
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
What the record says
- One of 59 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Adventris Pharmaceuticals
- Source Check — verify what Adventris Pharmaceuticals states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Adventris Pharmaceuticals for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Adventris PharmaceuticalsYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Adventris Pharmaceuticals: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.